FDA Staff Call for Further Study Considerations for Exa-Cel Ahead of Decision in Sickle Cell
October 29th 2023The therapy’s PDUFA date is scheduled for December 8, 2023, and an Advisory Committee is set to meet on October 31, 2023, to discuss the treatment’s potential approval for sickle cell disease.
Brett Kopelan, MA, on the Future Treatment of Epidermolysis Bullosa With Advanced Therapeutics
October 29th 2023In observance of Epidermolysis Bullosa Awareness Week, the executive director of debra of America discussed how a combination of advanced and topical approaches may represent the future of EB treatment.
David Rawlings, MD, on the Potential of Engineered Treg Cells to Treat Autoimmune Diseases
October 24th 2023The director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed preclinical research on overcoming limitations of Treg cells through genetic engineering.